Outlook Therapeutics Inc (OTLK)
7.58
-0.15
(-1.94%)
USD |
NASDAQ |
May 10, 16:00
7.58
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Cash from Financing (Quarterly): -0.0032M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0032M |
| September 30, 2023 | 2.424M |
| June 30, 2023 | 3.296M |
| March 31, 2023 | -0.5971M |
| December 31, 2022 | 43.85M |
| September 30, 2022 | 1.626M |
| June 30, 2022 | -11.30M |
| March 31, 2022 | 2.608M |
| December 31, 2021 | 66.66M |
| September 30, 2021 | 3.776M |
| June 30, 2021 | 2.716M |
| March 31, 2021 | 43.35M |
| December 31, 2020 | 6.357M |
| September 30, 2020 | 0.6608M |
| June 30, 2020 | 26.16M |
| March 31, 2020 | 10.40M |
| December 31, 2019 | -0.0083M |
| September 30, 2019 | -0.0688M |
| June 30, 2019 | 24.33M |
| Date | Value |
|---|---|
| March 31, 2019 | 6.237M |
| December 31, 2018 | 8.528M |
| September 30, 2018 | -0.4223M |
| June 30, 2018 | 14.56M |
| March 31, 2018 | -0.1875M |
| December 31, 2017 | 20.40M |
| September 30, 2017 | 2.990M |
| June 30, 2017 | 5.768M |
| March 31, 2017 | 2.156M |
| December 31, 2016 | 5.717M |
| September 30, 2016 | -0.5048M |
| June 30, 2016 | 27.21M |
| March 31, 2016 | 4.271M |
| December 31, 2015 | 8.888M |
| September 30, 2015 | 18.00M |
| June 30, 2015 | 18.48M |
| March 31, 2015 | 2.853M |
| December 31, 2014 | 3.670M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.30M
Minimum
Jun 2022
66.66M
Maximum
Dec 2021
11.91M
Average
2.716M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Cutera Inc | -0.232M |
| Actinium Pharmaceuticals Inc | 14.77M |
| GT Biopharma Inc | 0.00 |
| Karyopharm Therapeutics Inc | 0.264M |
| Marinus Pharmaceuticals Inc | 0.661M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -13.03M |
| Free Cash Flow | -47.10M |
| Free Cash Flow Per Share (Quarterly) | -1.002 |
| Free Cash Flow Yield | -48.09% |